Read the full stored bill text
Substitute House BILL No. 2250
AN A CT concerning health and healthcare; relating to certain medications; relating to
treatment of sexually transmitted infection treatment; permitting the use of expedited
partner therapy for the treatment thereof; authorizing a licensed private psychiatric
hospital to maintain a stock supply of emergency medication kits for pharmaceutical
emergencies; allowing for the use of expired emergency opioid antagonists to treat an
opioid overdose; permitting first responders to distribute and administer expired
emergency opioid antagonists; permitting a pharmacist to distribute epinephrine
delivery systems to a school for emergency medication kits; amending definitions
related to medication in schools to allow for use of epinephrine delivery systems;
amending K.S.A. 72-6282 and K.S.A. 2025 Supp. 22-2312 , 65-1680, 65-16,127 and
72-6283 and repealing the existing sections.
Be it enacted by the Legislature of the State of Kansas:
New Section 1. (a) As used in this section:
(1) "Department" means the department of health and
environment.
(2) "Expedited partner therapy" means to prescribe, administer,
dispense or otherwise provide antimicrobial drugs to a sexual partner of
a patient clinically diagnosed by a healthcare provider as infected with
a sexually transmitted disease without a physical examination of such
sexual partner.
(3) "Healthcare provider" means a practitioner or mid-level
practitioner as those terms are defined in K.S.A. 65-1626, and
amendments thereto.
(4) "Pharmacist" means a person licensed by the state board of
pharmacy to practice pharmacy.
(5) "Secretary" means the secretary of health and environment or
the secretary's designee.
(6) "Sexually transmitted disease" means any disease transmitted
through sexual contact, defined by rules and regulations adopted by the
secretary as a reportable infectious disease under K.S.A. 65-118, and
amendments thereto, and designated as appropriate for expedited
partner therapy by rules and regulations adopted by the secretary.
(b) (1) A healthcare provider who clinically diagnoses a patient
with a sexually transmitted disease may provide expedited partner
therapy if, in the professional judgment of the healthcare provider, the
patient's sexual partner is unlikely or unable to present for examination,
testing and treatment.
(2) A healthcare provider who provides expedited partner therapy
shall provide counseling to the patient, including distributing written
materials developed and provided by the department to be given by the
patient to the patient's sexual partner.
(3) A healthcare provider shall use expedited partner therapy only
for a patient's sexual partner who may have been exposed to a sexually
transmitted disease within 60 days immediately prior to the patient's
clinical diagnosis and who is able to be contacted and identified by the
patient.
(4) A child who is 16 years of age or older may consent to receive
expedited partner therapy when no parent or guardian is immediately
available.
(c) (1) No healthcare provider or pharmacist shall be liable for
civil damages resulting from any act or omission in good faith
compliance with the provisions of this section, including civil damages
for refusing to provide expedited partner therapy, other than an act or
omission constituting gross negligence or intentional or reckless
misconduct.
(2) No healthcare provider or pharmacist shall be subject to
disciplinary action by the state board of healing arts, the board of
nursing or the state board of pharmacy, as applicable, on the basis of an
act or omission in good faith compliance with the provisions of this
section, other than an act or omission constituting gross negligence or
Substitute for HOUSE BILL No. 2250—page 2
intentional or reckless misconduct.
(d) The department shall include the following information in
written materials developed and provided for distribution as required by
subsection (b)(2):
(1) A warning that a woman who is pregnant or might be pregnant
should not take certain antibiotics and should immediately contact a
healthcare provider for an examination;
(2) information about the antimicrobial drug and dosage provided
or prescribed, including a warning that a sexual partner who has a
history of allergy to the drug or the pharmaceutical class of drug should
not take the drug and should immediately contact a healthcare provider
for examination;
(3) information about the treatment and prevention of sexually
transmitted diseases;
(4) the requirement of sexual abstinence until a period of time
after treatment to prevent infecting other sexual partners;
(5) notification of the importance of the sexual partners receiving
examination and testing for human immunodeficiency virus and other
sexually transmitted diseases and information about available
resources;
(6) notification of the risk to the patient, the patient's sexual
partner and the general public if the sexually transmitted disease is not
completely and successfully treated;
(7) the responsibility of the sexual partner to inform the sexual
partner's own sexual partners of the risk of sexually transmitted disease
and the importance of prompt examination and treatment by a
healthcare provider; and
(8) such other information deemed necessary by the secretary.
(e) The secretary shall adopt rules and regulations as necessary to
implement and administer this section.
New Sec. 2. (a) A licensed private psychiatric hospital that utilizes
the services of a pharmacist may stock and maintain an emergency
medication kit approved by such hospital's medical staff and
pharmacist.
(b) The emergency medication kit shall be used only in emergency
cases under the supervision and direction of a prescriber and a
pharmacist who shall have supervisory responsibility of maintaining
such kit.
(c) Drugs in an emergency medication kit shall be maintained
under the control of the pharmacist-in-charge of the pharmacy from
which the kit came until administered to the patient upon the proper
order of a practitioner.
(d) Drugs contained within the emergency medication kit may
include controlled substances, but in such a case, a pharmaceutical
services committee shall be responsible for specifically limiting the
type and quantity of controlled substance to be placed in each
emergency kit.
(e) Administration of controlled substances contained within the
emergency medication kit shall be in compliance with the provisions of
the uniform controlled substances act.
(f) The pharmacist-in-charge of the licensed private psychiatric
hospital shall be responsible for developing procedures, proper control
and accountability for the emergency kit and maintain complete and
accurate records.
(g) The secretary and the state board of pharmacy shall jointly
adopt such rules and regulations that are necessary to effectuate the
provisions of this act. Such rules and regulations shall include, but not
be limited to, the contents of the emergency medication kit, procedures
for the control and accountability of the emergency medication kit,
recordkeeping and storage of the emergency medication kit.
(h) As used in this section:
(1) "Emergency medication kit" means a stock supply of such
drugs as are required to meet the immediate therapeutic needs of
patients when the drug is not available from another source in sufficient
Substitute for HOUSE BILL No. 2250—page 3
time to prevent harm;
(2) "licensed private psychiatric hospital" means an institution,
excluding state institutions as defined in K.S.A. 76-12a01, and
amendments thereto, that is primarily engaged in providing services, by
and under the supervision of qualified professionals, for the diagnosis
and treatment of mentally ill individuals that is licensed pursuant to
K.S.A. 39-2008, and amendments thereto;
(3) "pharmacist" means the same as defined in K.S.A. 65-1626,
and amendments thereto;
(4) "pharmacist-in-charge" means the same as defined in K.S.A.
65-1626, and amendments thereto;
(5) "practitioner" means the same as defined in K.S.A. 65-1626,
and amendments thereto;
(6) "prescriber" means the same as defined in K.S.A. 65-1626, and
amendments thereto; and
(7) "secretary" means the secretary of health and environment.
Sec. 3 K.S.A. 2025 Supp. 22-2312 is hereby amended to read as
follows: 22-2312. (a) A law enforcement officer shall not take a person
into custody based solely on the commission of an offense described in
subsection (b) if the law enforcement officer, after making a reasonable
determination and considering the facts and surrounding circumstances,
reasonably believes that the person:
(1) (A) Initiated contact with a law enforcement officer, law
enforcement agency or emergency medical services and requested
medical assistance on the person's own behalf because the person
reasonably believed they needed medical assistance as a result of the
use of a controlled substance; and
(B) cooperated with law enforcement officers and emergency
medical services personnel in providing such medical assistance;
(2) (A) was a person who rendered aid , including administering
an emergency opioid antagonist, to another person who reasonably
appeared to need medical assistance as a result of the use of a
controlled substance or initiated contact with a law enforcement officer,
law enforcement agency or emergency medical services and requested
medical assistance for another person who reasonably appeared to need
medical assistance as a result of the use of a controlled substance;
(B) provided such person's full name and any other relevant
information that is necessary to provide the medical assistance
described in paragraph (2)(A) as requested by law enforcement or
emergency medical services;
(C) remained at the scene with the person who reasonably
appeared to need medical assistance until emergency medical services
personnel and law enforcement officers arrived; and
(D) cooperated with emergency medical services personnel and
law enforcement officers in providing such medical assistance; or
(3) (A) was the person who reasonably appeared to need medical
assistance as a result of the use of a controlled substance as described
in subsection (a)(2)(A); and
(B) cooperated with emergency medical services personnel and
law enforcement officers in providing such medical assistance.
(b) (1) Except as provided in paragraph (2), each person who
meets the criteria in subsection (a) is immune from criminal
prosecution for a violation of K.S.A. 21-5706 or 21-5709(b)(2), and
amendments thereto, and any city ordinance or county resolution
prohibiting the acts prohibited by K.S.A. 21-5706 or 21-5709(b)(2),
and amendments thereto.
(2) No person is immune from criminal prosecution as provided in
paragraph (1) if the quantity of controlled substances found at the scene
of the encounter with law enforcement would be sufficient to create a
rebuttable presumption of an intent to distribute as described in K.S.A.
21-5705(e), and amendments thereto.
(c) The provisions of this section shall not apply to a person
seeking medical assistance during the course of the execution of an
arrest warrant or search warrant or a lawful search.
Substitute for HOUSE BILL No. 2250—page 4
(d) Nothing in this section shall be construed to preclude a person
who is immune from criminal prosecution pursuant to this section from
being prosecuted based on evidence obtained from an independent
source.
(e) A person shall not be allowed to initiate or maintain an action
against a law enforcement officer, or the officer's employer, based on
the officer's compliance or failure to comply with this section. Except
in cases of reckless or intentional misconduct, a law enforcement
officer shall be immune from liability for arresting a person who is later
determined to be immune from prosecution pursuant to this section.
(f) As used in this section:
(1) "Controlled substance" means the same as defined in K.S.A.
21-5701, and amendments thereto; and.
(2) "Emergency opioid antagonist" means an intranasal form of a
drug that inhibits the effects of opioids and that is approved by the
federal food and drug administration for the treatment of an opioid
overdose. "Emergency opioid antagonist" includes an expired
emergency opioid antagonist up to 10 years past such emergency
opioid antagonist's expiration date.
(2)(3) "Law enforcement officer" means the same as defined in
K.S.A. 21-5111, and amendments thereto.
Sec. 4. K.S.A. 2025 Supp. 65-16,127 is hereby amended to read as
follows: 65-16,127. (a) As used in this section:
(1) "Bystander" means a family member, friend, caregiver or other
person in a position to assist a person who the family member, friend,
caregiver or other person believes, in good faith, to be experiencing an
opioid overdose.
(2) "Emergency opioid antagonist" means any drug that inhibits
the effects of opioids and that is approved by the United States food
and drug administration for the treatment of an opioid overdose. Except
as provided in subsection (h), "emergency opioid antagonist" includes
an expired emergency opioid antagonist up to 10 years past such
emergency opioid antagonist's expiration date.
(3) "First responder" includes any emergency medical service
provider, as defined by K.S.A. 65-6112, and amendments thereto, any
law enforcement officer, as defined by K.S.A. 22-2202, and
amendments thereto, and any actual member of any organized fire
department, whether regular or volunteer.
(4) "First responder agency" includes, but is not limited to, any
law enforcement agency, fire department or criminal forensic
laboratory of any city, county or the state of Kansas.
(5) "Opioid antagonist protocol" means the protocol established
by the state board of pharmacy pursuant to subsection (b).
(6) "Opioid overdose" means an acute condition including, but not
limited to, extreme physical illness, decreased level of consciousness,
respiratory depression, coma, mania or death, resulting from the
consumption or use of an opioid or another substance with which an
opioid was combined, or that a layperson would reasonably believe to
be resulting from the consumption or use of an opioid or another
substance with which an opioid was combined, and for which medical
assistance is required.
(7) "Patient" means a person believed to be at risk of experiencing
an opioid overdose.
(8) "School nurse" means a professional nurse licensed by the
board of nursing and employed by a school district to perform nursing
procedures in a school setting.
(9) "Healthcare provider" means a physician licensed to practice
medicine and surgery by the state board of healing arts, a licensed
dentist, a mid-level practitioner as defined by K.S.A. 65-1626, and
amendments thereto, or any person authorized by law to prescribe
medication.
(b) The state board of pharmacy shall issue a statewide opioid
antagonist protocol that establishes requirements for a licensed
pharmacist to dispense emergency opioid antagonists to a person
Substitute for HOUSE BILL No. 2250—page 5
pursuant to this section. The opioid antagonist protocol shall include
procedures to ensure accurate recordkeeping and education of the
person to whom the emergency opioid antagonist is furnished,
including, but not limited to: Opioid overdose prevention, recognition
and response; safe administration of an emergency opioid antagonist;
potential side effects or adverse events that may occur as a result of
administering an emergency opioid antagonist; a requirement that the
administering person immediately contact emergency medical services
for a patient; and the availability of drug treatment programs.
(c) A pharmacist may furnish an emergency opioid antagonist to a
patient or bystander subject to the requirements of this section, the
pharmacy act of the state of Kansas and any rules and regulations
adopted by the state board of pharmacy thereunder.
(d) A pharmacist furnishing an emergency opioid antagonist
pursuant to this section may not permit the person to whom the
emergency opioid antagonist is furnished to waive any consultation
required by this section or any rules and regulations adopted
thereunder.
(e) Any first responder, scientist or technician operating under a
first responder agency or school nurse is authorized to possess, store,
distribute and administer emergency opioid antagonists as clinically
indicated, provided that all personnel with access to emergency opioid
antagonists are trained, at a minimum, on the following:
(1) Techniques to recognize signs of an opioid overdose;
(2) standards and procedures to store, distribute and administer an
emergency opioid antagonist;
(3) emergency follow-up procedures, including the requirement to
summon emergency ambulance services either immediately before or
immediately after administering an emergency opioid antagonist to a
patient; and
(4) inventory requirements and reporting any administration of an
emergency opioid antagonist to a healthcare provider.
(f) (1) Any first responder agency electing to provide an
emergency opioid antagonist to its employees or volunteers for the
purpose of administering the emergency opioid antagonist shall procure
the services of a physician to serve as physician medical director for the
first responder agency's emergency opioid antagonist program.
(2) The first responder agency shall utilize the physician medical
director or a licensed pharmacist for the purposes of:
(A) Obtaining a supply of emergency opioid antagonists;
(B) receiving assistance developing necessary policies and
procedures that comply with this section and any rules and regulations
adopted thereunder;
(C) training personnel; and
(D) coordinating agency activities with local emergency
ambulance services and medical directors to provide quality assurance
activities.
(3) A law enforcement agency shall be exempt from this
subsection unless electing to provide an emergency opioid antagonist
dispensed or furnished pursuant to the opioid antagonist protocol in
subsection (b).
(g) (1) Any healthcare provider or pharmacist who, in good faith
and with reasonable care, prescribes or dispenses an emergency opioid
antagonist pursuant to this section shall not, by an act or omission, be
subject to civil liability, criminal prosecution or any disciplinary or
other adverse action by a professional licensure entity arising from the
healthcare provider or pharmacist prescribing or dispensing the
emergency opioid antagonist.
(2) Any patient, bystander, school nurse, or a first responder,
scientist or technician operating under a first responder agency, who, in
good faith and with reasonable care, receives and administers an
emergency opioid antagonist pursuant to this section to a person
experiencing a suspected opioid overdose shall not, by an act or
omission, be subject to civil liability or criminal prosecution, unless
Substitute for HOUSE BILL No. 2250—page 6
personal injury results from the gross negligence or willful or wanton
misconduct in the administration of the emergency opioid antagonist.
(3) Any first responder agency employing or contracting any
person that, in good faith and with reasonable care, administers an
emergency opioid antagonist pursuant to this section to a person
experiencing a suspected opioid overdose shall not, by an act or
omission, be subject to civil liability, criminal prosecution, any
disciplinary or other adverse action by a professional licensure entity or
any professional review.
(h) Pharmacists, healthcare providers and school nurses shall not
prescribe, dispense, distribute or furnish an expired emergency opioid
antagonist.
(i) The state board of pharmacy shall adopt rules and regulations
as may be necessary to implement the provisions of this section prior to
January 1, 2018.
(i)(j) This section shall be a part of and supplemental to the
pharmacy act of the state of Kansas.
Sec. 5. K.S.A. 2025 Supp. 65-1680 is hereby amended to read as
follows: 65-1680. (a) A pharmacist may distribute a stock supply of
standard-dose and pediatric-dose epinephrine auto-injectors delivery
systems to a school pursuant to a prescription made pursuant to K.S.A.
72-6283, and amendments thereto, from a physician or mid-level
practitioner in the name of the school. A pharmacist who distributes a
stock supply of standard-dose or pediatric-dose epinephrine auto-
injectors delivery systems to a school shall not be liable for civil
damages resulting from the administration of such medication pursuant
to this section, K.S.A. 65-2872b or 72-6283, and amendments thereto.
(b) A pharmacist may distribute a stock supply of albuterol
metered-dose inhalers, albuterol solution and spacers to a school
pursuant to a prescription made pursuant to K.S.A. 72-6283, and
amendments thereto, from a physician or mid-level practitioner in the
name of the school. A pharmacist who distributes a stock supply of
albuterol metered-dose inhalers, albuterol solution or spacers to a
school shall not be liable for civil damages resulting from the
administration of such medication pursuant to this section, K.S.A. 65-
2872b or 72-6283, and amendments thereto.
(c) The terms used in this section mean the same as defined in
K.S.A. 72-6283, and amendments thereto.
Sec. 6. K.S.A. 72-6282 is hereby amended to read as follows: 72-
6282. (a) As used in this section:
(1) "Medication" means a medicine prescribed by a health care
healthcare provider for the treatment of anaphylaxis or asthma ,
including, but not limited to, any medicine defined in section 201 of the
federal food, drug and cosmetic act, inhaled bronchodilators and auto-
injectible epinephrine delivery systems.
(2) "Health careHealthcare provider" means:
(A) A physician licensed by the state board of healing arts to
practice medicine and surgery; or
(B) an advanced practice registered nurse issued a license pursuant
to K.S.A. 65-1131, and amendments thereto, who has authority to
prescribe drugs as provided by K.S.A. 65-1130, and amendments
thereto; or (C) a physician assistant licensed pursuant to the physician
assistant licensure act who has authority to prescribe drugs prior to
January 11, 2016, pursuant to a written protocol with a responsible
physician under K.S.A. 65-28a08, and amendments thereto, and on and
after January 11, 2016, pursuant to a written agreement with a
supervising physician under K.S.A. 65-28a08, and amendments thereto
a mid-level practitioner as such term is defined in K.S.A. 65-1626, and
amendments thereto.
(3) "School" means any public or accredited nonpublic school.
(4) "Self-administration" means a student's discretionary use of
such student's medication pursuant to a prescription or written direction
from a health care healthcare provider.
(b) Each school district shall adopt a policy authorizing the self-
Substitute for HOUSE BILL No. 2250—page 7
administration of medication by students enrolled in kindergarten or
any of the grades one through 12. A student shall meet all requirements
of a policy adopted pursuant to this subsection. Such policy shall
include:
(1) A requirement of a written statement from the student's health
care healthcare provider stating the name and purpose of the
medication;, the prescribed dosage ;, the time the medication is to be
regularly administered, and any additional special circumstances under
which the medication is to be administered ;, and the length of time for
which the medication is prescribed;
(2) a requirement that the student has demonstrated to the health
care healthcare provider or such provider's designee and the school
nurse or such nurse's designee the skill level necessary to use the
medication and any device that is necessary to administer such
medication as prescribed. If there is no school nurse, the school shall
designate a person for the purposes of this subsection;
(3) a requirement that the health care healthcare provider has
prepared a written treatment plan for managing asthma or anaphylaxis
episodes of the student and for medication use by the student during
school hours;
(4) a requirement that the student's parent or guardian has
completed and submitted to the school any written documentation
required by the school, including the treatment plan prepared as
required by paragraph (3) and documents related to liability;
(5) a requirement that all teachers responsible for the student's
supervision shall be notified that permission to carry medications and
self-medicate has been granted; and
(6) any other requirement imposed by the school district pursuant
to this section and K.S.A. 72-1138(e), and amendments thereto.
(c) A school district shall require annual renewal of parental
authorization for the self-administration of medication.
(d) A school district, and its officers, employees and agents, which
that authorizes the self-administration of medication in compliance
with the provisions of this section shall not be held liable in any action
for damage, injury or death resulting directly or indirectly from the
self-administration of medication.
(e) A school district shall provide written notification to the parent
or guardian of a student that the school district and its officers,
employees and agents are not liable for damage, injury or death
resulting directly or indirectly from the self-administration of
medication. The parent or guardian of the student shall sign a statement
acknowledging that the school district and its officers, employees or
agents incur no liability for damage, injury or death resulting directly or
indirectly from the self-administration of medication and agreeing to
release, indemnify and hold the school and its officers, employees and
agents, harmless from and against any claims relating to the self-
administration of such medication.
(f) A school district shall require that any back-up medication
provided by the student's parent or guardian be kept at the student's
school in a location to which the student has immediate access in the
event of an asthma or anaphylaxis emergency.
(g) A school district shall require that information described in
subsection (b)(3) and (4) be kept on file at the student's school in a
location easily accessible in the event of an asthma or anaphylaxis
emergency.
(h) An authorization granted pursuant to subsection (b) shall allow
a student to possess and use such student's medication at any place
where a student is subject to the jurisdiction or supervision of the
school district or its officers, employees or agents.
(i) A board of education may adopt a policy pursuant to K.S.A.
72-1138(e), and amendments thereto, which that:
(1) Imposes requirements relating to the self-administration of
medication which that are in addition to those required by this section;
and
Substitute for HOUSE BILL No. 2250—page 8
(2) establishes a procedure for , and the conditions under which ,
the authorization for the self-administration of medication may be
revoked.
Sec. 7. K.S.A. 2025 Supp. 72-6283 is hereby amended to read as
follows: 72-6283. (a) As used in this section, K.S.A. 65-1680 and 65-
2872b, and amendments thereto:
(1) "Albuterol" means a short-acting beta-2 agonist-inhaled
medication, otherwise known as a bronchodilator, that is prescribed by
a physician or mid-level practitioner for the treatment of respiratory
distress.
(2) "Albuterol metered-dose inhaler" means a portable drug
delivery system containing a canister of multiple premeasured doses of
albuterol in a device actuator.
(3) "Albuterol solution" means a liquid form of albuterol for use
with a nebulizer.
(4) "Anaphylaxis" or "anaphylactic reaction" means a sudden,
severe and potentially life-threatening multi-system allergic reaction.
(5) "Designated school personnel" means an employee, officer,
agent or volunteer of a school who has completed training, documented
by the school nurse, a physician or a mid-level practitioner, to
administer emergency medication on a voluntary basis outside of the
scope of employment.
(6) "Emergency medication" means epinephrine or albuterol.
(7) "Epinephrine" means a medication prescribed by a physician
or mid-level practitioner for the emergency treatment of anaphylaxis
prior to the arrival of emergency medical system responders.
(8) "Epinephrine auto-injector delivery system" means a device
that automatically injects is approved by the federal food and drug
administration, contains a premeasured dose of epinephrine and is
used to administer epinephrine into the human body.
(9) "Mid-level practitioner" means the same as such term is
defined in K.S.A. 65-1626, and amendments thereto.
(10) "Nebulizer" means a device that is used to change a liquid
medication to a fine spray of liquid or mist for the administration of the
medication through inhalation.
(11) "Pharmacist" means the same as such term is defined in
K.S.A. 65-1626, and amendments thereto.
(12) "Physician" means any person licensed by the state board of
healing arts to practice medicine and surgery.
(13) "Respiratory distress" means impaired ventilation of the
respiratory system or impaired oxygenation of the blood.
(14) "School" means any school operated by a school district
organized under the laws of this state or any accredited nonpublic
school that provides education to elementary or secondary students.
(15) "School nurse" means a registered nurse licensed by the
board of nursing to practice nursing in Kansas or a licensed practical
nurse working under a registered nurse who is employed by a school to
perform nursing services in a school setting.
(16) "Spacer" means a holding chamber that is used to optimize
the delivery of aerolized albuterol from an albuterol metered-dose
inhaler.
(17) "Stock supply" means an appropriate quantity of emergency
medication as recommended by a physician or mid-level practitioner.
(b) (1) A school may maintain a stock supply of emergency
medication upon obtaining a prescription from a physician or mid-level
practitioner in the name of the school. A physician or mid-level
practitioner shall review the school's policies and procedures
established pursuant to subsection (c) prior to prescribing such
emergency medication.
(2) A stock supply of epinephrine may consist of one or more
standard-dose or pediatric-dose epinephrine auto-injectors delivery
systems. A school nurse or designated school personnel may administer
such epinephrine in an emergency situation to any individual who
displays the signs and symptoms of anaphylaxis at school, on school
Substitute for HOUSE BILL No. 2250—page 9
property or at a school-sponsored event if such school nurse or
designated school personnel reasonably believes that an individual is
exhibiting the signs and symptoms of an anaphylactic reaction.
(3) A stock supply of albuterol may consist of one or more
albuterol metered-dose inhalers, one or more doses of albuterol solution
and one or more spacers or nebulizers. A school nurse or designated
school personnel may administer such albuterol in an emergency
situation to any individual who displays the signs and symptoms of
respiratory distress at school, on school property or at a school-
sponsored event if such school nurse or designated school personnel
reasonably believes that an individual is exhibiting the signs and
symptoms of respiratory distress.
(c) A school that maintains a stock supply of emergency
medication shall establish school policies and procedures relating to:
(1) Storage of the emergency medication, which shall require that
the emergency medication is stored:
(A) In a safe location that is readily accessible to the school nurse
or designated school personnel; and
(B) in accordance with manufacturer temperature
recommendations;
(2) periodic monitoring of the inventory and expiration dates of
emergency medication;
(3) administration of emergency medication by designated school
personnel; and
(4) training requirements for designated school personnel, which
shall be conducted b y a school nurse, physician or mid-level
practitioner on not less than on an annual basis for such designated
school personnel. Such training shall include, but not be limited to, the
following:
(A) Recognition of the symptoms of anaphylaxis and respiratory
distress;
(B) administration of emergency medication;
(C) calling for emergency medical system responders;
(D) monitoring the condition of an individual after emergency
medication has been administered;
(E) notification of the parent, guardian or next of kin; and
(F) safe disposal and sanitation of used equipment.
(d) A school shall publish information related to the school's
emergency medication policies and procedures and shall maintain
records of the training provided to designated school personnel.
(e) A school may accept monetary gifts, grants and donations to
carry out the provisions of this section or may accept epinephrine auto-
injectors delivery systems , albuterol metered-dose inhalers, albuterol
solution, spacers or nebulizers from a manufacturer or wholesaler.
Substitute for HOUSE BILL No. 2250—page 10
Sec. 8. K.S.A. 72-6282 and K.S.A. 2025 Supp. 22-2312, 65-1680,
65-16,127 and 72-6283 are hereby repealed.
Sec. 9. This act shall take effect and be in force from and after its
publication in the statute book.
I hereby certify that the above BILL originated in the HOUSE, and was
adopted by that body
HOUSE adopted
Conference Committee Report
Speaker of the House.
Chief Clerk of the House.
Passed the SENATE
as amended
SENATE adopted
Conference Committee Report
President of the Senate.
Secretary of the Senate.
APPROVED
Governor.